Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
13 mai 2024 17h01 HE
|
Turnstone Biologics Corp.
Turnstone Biologics Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference
08 mai 2024 09h00 HE
|
Turnstone Biologics Corp.
Dr. Sammy Farah, Turnstone's President and CEO, to present at the 2024 Bank of America Securities Health Care Conference in Las Vegas, NV.
Turnstone Biologics Appoints William Waddill to its Board of Directors
16 avr. 2024 09h00 HE
|
Turnstone Biologics Corp.
Turnstone Biologics appoints biotechnology industry veteran, William Waddill, to its Board of Directors.
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights
21 mars 2024 17h06 HE
|
Turnstone Biologics Corp.
Turnstone reports fourth quarter and full year 2023 financial results and provides recent business highlights.
Turnstone Biologics to Participate in Upcoming Investor Conferences
21 févr. 2024 06h00 HE
|
Turnstone Biologics Corp.
Turnstone to present and participate in TD Cowen 44th Annual Global Health Care Conference and Leerink Partners Global Biopharma Conference 2024.
Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.
20 févr. 2024 17h00 HE
|
Turnstone Biologics Corp.
Turnstone announced with sadness that the Company's Chief Legal Officer passed away following prolonged battle with cancer.
Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference
27 nov. 2023 06h00 HE
|
Turnstone Biologics Corp.
Dr. Sammy Farah, President and CEO of Turnstone, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York.
Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
09 nov. 2023 21h49 HE
|
Turnstone Biologics Corp.
Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
03 nov. 2023 06h00 HE
|
Turnstone Biologics Corp.
Posters showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for solid tumors.
Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber
30 oct. 2023 06h00 HE
|
Turnstone Biologics Corp.
Internationally recognized cancer immunotherapy thought leader, Dr. Weber, will help guide Turnstone’s continued advancement of its Selected TIL therapies